Document is current

Article History

Received: 1 July 2020

Accepted: 4 July 2020

First Online: 31 July 2020

Ethics approval and consent to participate

: Health Research Authority and Research Ethics Committee, Bristol HRA Centre (REC reference: 20/SC/0201), 24^th April 2020I certify that this trial has received appropriate ethical approval as described above.We will obtain consent from all participants entering into the ACCORD study.

: Not applicable

: GD, RR, KP, MC, RD, MS-H, RW, NM-A, JD and JS declare no competing interests. MOK has carried out consulting work for AZ. AdS has received research grants/personal fees/travel from AstraZeneca, Bayer, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pfizer and Medimmune. AG has received consulting fees paid to institution from GlaxoSmithKline, Bristol-Myers Squibb and Baxter Healthcare. CS has received research funding from GlaxoSmithKline and AstraZeneca and is a founder of Exvastat. CP is a member of Advisory Boards of Immune Regulation Ltd, Eurodrug, Sativa, holds NED positions with Immune Regulation Ltd, PrEP Biopharm, EpiEndo and Babraham Biotechnology Ltd, a trustee of Babraham Institute and Fraunhofer Institute of Experimental Medicine and Toxicology and holds equity in Immune Regulation Ltd, and Verona Pharma. DS has received research grants/personal fees/travel from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Genentech, GlaxoSmithKline, Glenmark, Menarini, Mundipharma, Novartis, Peptinnovate, Pfizer, Pulmatrix, Teva, Therevance and Verona. GG has received research grants from Jannsenn-Cilag, AstraZeneca, Novartis Pharma, Astex, Roche, Heartflow, Celldex, Bristol-Myers Squibb and BioNTech. JC has received research grants/personal fees from Astrazeneca, Boehringer Ingelheim, Glaxosmithkline, Insmed and Gilead Sciences. LM has received research grants/personal fees/travel from Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Merck, AstraZeneca, Bionorica, Vernalis, Afferent, Merck, Bellus, Bayer, Celerio & Sanofi. L-PH has received research grants from Boehringer Ingleheim and Celgene. KL is Medical Director of Respiratory Innovation Wales and a Director of Bond Digital Health and Iomics Ltd and has received sponsorship to attend and speak at international meetings from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Pfizer. TF has received sponsorship to attend and speak at international meetings, honoraria for lecturing or attending advisory boards, from Gilead, Pfizer and Menarini and is an advisor to the NICE/NHSE AMR novel antimicrobial value assessment/reimbursement project stakeholder advisory group. TW has received research grants/personal frees/travel from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Synairgen & mymhealth.